Astec LifeSciences Limited (ASTEC) — FY26 Annual Report | 31 July 2026 (3 announcements)

The 32nd Annual General Meeting of Astec LifeSciences Limited was held on 31 July 2026 via video conference, where shareholders approved the adoption of financial statements for FY2025-26, re-appointed Mr. Ashok V. Hiremath as Director, and ratified the remuneration of Tapan Gaitonde & Co. as Cost Auditor for FY2026-27. All resolutions passed with requisite majority, with e-voting conducted through NSDL from 26 to 30 July 2026. The filing confirms compliance with SEBI and MCA regulations, including electronic voting procedures, unclaimed dividend transfers to IEPF, and procedural requirements for shareholder participation. It also includes disclosures on director appointments, committee compositions, and governance practices, alongside material risks such as market cyclicality, pricing volatility, and foreign exchange fluctuations. The company reported a consolidated net loss of [amount not verified] for FY2025-26, improved from [amount not verified] in the prior year, with revenue growth driven by exports and CDMO segment expansion. Strategic focus areas include CDMO capabilities, sustainability initiatives (EcoVadis Gold rating, 26.7% renewable energy use), and risk management frameworks. The filing emphasizes governance compliance, including zero material related party transactions, adherence to sexual harassment policies, and stakeholder engagement practices.

The 32nd Annual General Meeting of Astec LifeSciences Limited was held on July 31, 2026, via video conferencing, where all agenda items including adoption of financial statements, re-appointment of a director, and ratification of cost auditor remuneration were passed with over 99.99% approval. The filing confirms compliance with regulatory requirements, includes detailed voting results, and outlines shareholder procedures for remote participation. It also details strategic focus on CDMO expansion, sustainability initiatives, and material risks like export exposure and raw material dependency, while reporting consolidated revenue of ₹45,321.65 Lakh and improved profitability trends.

The 32nd Annual General Meeting of Astec LifeSciences Limited was held on July 31, 2026, via video conferencing, where shareholders approved the adoption of FY2025-26 financial statements, re-appointed Director Ashok V. Hiremath, and ratified the cost auditor remuneration for FY2026-27 with over 99.9% approval across all resolutions. The filing confirms compliance with SEBI and MCA regulations, e-voting via NSDL, and statutory requirements. Financial highlights include consolidated revenue of ₹45,321.65 Lakh for FY2025-26, a loss after tax of ₹8,087.62 Lakh, and a rights issue raising ₹249.35 Crore. Governance disclosures emphasize board composition, committee functions, and adherence to ESG principles, including waste management, safety excellence (94% UA/UC compliance), and sustainability initiatives like SBTi targets. Risks include geopolitical trade tensions, raw material dependency, and weather volatility affecting demand.